Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03467958 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
A Phase 3 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT03467958 is a Phase 3 study that was terminated before completion, run by Celgene. The registered enrollment target is 854 participants.
The verdict
NCT03467958, a Phase 3 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Interventions
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2018-08-24 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03467958
The ClinicalTrials.gov registry entry for NCT03467958 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 854 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ozanimod is the first listed.
NCT03467958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03467958 about?
NCT03467958 is a clinical study titled "An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease". This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
What is the current status of trial NCT03467958?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2018-08-24. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT03467958?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT03467958?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.